Elevated de novo protein synthesis in FMRP-deficient human neurons and its correction by metformin treatment
Tóm tắt
FXS is the most common genetic cause of intellectual (ID) and autism spectrum disorders (ASD). FXS is caused by loss of FMRP, an RNA-binding protein involved in the translational regulation of a large number of neuronal mRNAs. Absence of FMRP has been shown to lead to elevated protein synthesis and is thought to be a major cause of the synaptic plasticity and behavioural deficits in FXS. The increase in protein synthesis results in part from abnormal activation of key protein translation pathways downstream of ERK1/2 and mTOR signalling. Pharmacological and genetic interventions that attenuate hyperactivation of these pathways can normalize levels of protein synthesis and improve phenotypic outcomes in animal models of FXS. Several efforts are currently underway to trial this strategy in patients with FXS. To date, elevated global protein synthesis as a result of FMRP loss has not been validated in the context of human neurons. Here, using an isogenic human stem cell-based model, we show that de novo protein synthesis is elevated in FMRP-deficient neural cells. We further show that this increase is associated with elevated ERK1/2 and Akt signalling and can be rescued by metformin treatment. Finally, we examined the effect of normalizing protein synthesis on phenotypic abnormalities in FMRP-deficient neural cells. We find that treatment with metformin attenuates the increase in proliferation of FMRP-deficient neural progenitor cells but not the neuronal deficits in neurite outgrowth. The elevated level of protein synthesis and the normalization of neural progenitor proliferation by metformin treatment were validated in additional control and FXS patient-derived hiPSC lines. Overall, our results validate that loss of FMRP results in elevated de novo protein synthesis in human neurons and suggest that approaches targeting this abnormality are likely to be of partial therapeutic benefit in FXS.
Tài liệu tham khảo
Hagerman RJ, et al. Fragile X syndrome. Nat Rev. Disease primers. 2017. https://doi.org/10.1038/nrdp.2017.65.
Verkerk AJMH, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991. https://doi.org/10.1016/0092-8674(91)90397-H.
Turner G. Fragile X syndrome: diagnosis, treatment and research. J Med Genet. 1997. https://doi.org/10.1136/jmg.34.5.439.
Darnell JC, et al. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell. 2001. https://doi.org/10.1016/S0092-8674(01)00566-9.
Darnell JC, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011. https://doi.org/10.1016/j.cell.2011.06.013.
Qin M, et al. Altered cerebral protein synthesis in fragile X syndrome: studies in human subjects and knockout mice. J Cereb Blood Flow Metab. 2013. https://doi.org/10.1038/jcbfm.2012.205.
Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the Fmr1 null mouse. J Neurosci. 2005. https://doi.org/10.1523/JNEUROSCI.0093-05.2005.
Osterweil EK, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron. 2013. https://doi.org/10.1016/j.neuron.2012.01.034.
Sharma A, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci. 2010. https://doi.org/10.1523/JNEUROSCI.3696-09.2010.
Dölen G, et al. Correction of fragile X syndrome in mice. Neuron. 2007. https://doi.org/10.1016/j.neuron.2007.12.001.
Henderson C, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012. https://doi.org/10.1126/scitranslmed.3004218.
Bhattacharya A, et al. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron. 2012. https://doi.org/10.1016/j.neuron.2012.07.022.
Michalon A, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron. 2012. https://doi.org/10.1016/j.neuron.2012.03.009.
Jacquemont S, et al. Protein synthesis levels are increased in a subset of individuals with fragile X syndrome. Hum Mol Genet. 2018. https://doi.org/10.1093/hmg/ddy099.
Gross C, Bassell GJ. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110β-selective inhibitor. Mol Med. 2012. https://doi.org/10.2119/molmed.2011.00363.
Kumari D, et al. Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs. Hum Mutat. 2014. https://doi.org/10.1002/humu.22699.
Utami KH, et al. Integrative analysis identifies key molecular signatures underlying neurodevelopmental deficits in fragile X syndrome. Biol Psych. 2020. https://doi.org/10.1016/j.biopsych.2020.05.005.
Achuta VS, et al. Metabotropic glutamate receptor 5 responses dictate differentiation of neural progenitors to NMDA-responsive cells in fragile X syndrome. Dev Neurobiol. 2016.
Li W, et al. Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc Natl Acad Sci U S A. 2011. https://doi.org/10.1073/pnas.1014041108.
Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009. https://doi.org/10.1038/nmeth.1314.
Osterweil EK, Krueger DD, Reinhold K, Bear MF. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci. 2010. https://doi.org/10.1523/JNEUROSCI.3888-10.2010.
Brennand KJ, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011. https://doi.org/10.1038/nature09915.
Gantois I, et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med. 2017. https://doi.org/10.1038/nm.4335.
Howell JJ, et al. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017. https://doi.org/10.1016/j.cmet.2016.12.009.
Gillespie ZE, et al. Metformin induces the AP-1 transcription factor network in normal dermal fibroblasts. Sci Rep. 2019. https://doi.org/10.1038/s41598-019-41839-1.
Castren M, et al. Altered differentiation of neural stem cells in fragile X syndrome. Proc Natl Acad Sci. 2005. https://doi.org/10.1073/pnas.0508995102.
Luo Y, et al. Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet. 2010. https://doi.org/10.1371/journal.pgen.1000898.
Callan MA, et al. Fragile X protein controls neural stem cell proliferation in the Drosophila brain. Hum Mol Genet. 2010. https://doi.org/10.1093/hmg/ddq213.
Xiong ZS, et al. Effect of metformin on cell proliferation, apoptosis, migration and invasion in A172 glioma cells and its mechanisms. Mol Med Rep. 2019. https://doi.org/10.3892/mmr.2019.10369.
Liang X, et al. Effects of metformin on proliferation and apoptosis of human megakaryoblastic Dami and MEG-01 cells. J Pharmacol Sci. 2017. https://doi.org/10.1016/j.jphs.2017.08.003.
Xie W, et al. Metformin induces growth inhibition and cell cycle arrest by upregulating microRNA34a in renal cancer cells. Med Sci Monit. 2017. https://doi.org/10.12659/MSM.898710.
Sheridan SD, et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One. 2011. https://doi.org/10.1371/journal.pone.0026203.
M., T., L., K.-Y., M., S. & Ben-Yosef D. AO - Telias Liron; ORCID: http://orcid.org/0000-0002-9705-6697, M. O. http://orcid.org/000-0002-7632-6942 A. O.-K.-Y. Functional deficiencies in fragile X neurons derived from human embryonic stem cells. J Neurosci (2015).
Doers ME, et al. IPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth. Stem Cells Dev. 2014.
Richter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nat Rev Neurosci. 2015. https://doi.org/10.1038/nrn4001.
Berry-Kravis E. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome. Pediatr Neurol. 2014. https://doi.org/10.1016/j.pediatrneurol.2013.12.001.
Lee AW, Ventola P, Budimirovic D, Berry-Kravis E, Visootsak J. Clinical development of targeted fragile X syndrome treatments: an industry perspective. Brain Sci. 2018. https://doi.org/10.3390/brainsci8120214.
Erickson CA, et al. Fragile X targeted pharmacotherapy: lessons learned and future directions. J Neurodev Disord. 2017. https://doi.org/10.1186/s11689-017-9186-9.
Jeste SS, Geschwind DH. Clinical trials for neurodevelopmental disorders: at a therapeutic frontier. Sci Transl Med. 2016. https://doi.org/10.1126/scitranslmed.aad9874.
Wang X, et al. Activation of the ERK pathway contributes to the behavioral deficit of fragile X-syndrome. J Neurochem. 2012.
Monyak RE, et al. Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model. Mol Psychiatry. 2017. https://doi.org/10.1038/mp.2016.51.
Dy ABC, et al. Metformin as targeted treatment in fragile X syndrome. Clin Genet. 2018. https://doi.org/10.1111/cge.13039.
Protic D, et al. Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases. Mol Genet Genomic Med. 2019. https://doi.org/10.1002/mgg3.745.
Gantois I, Popic J, Khoutorsky A, Sonenberg N. Metformin for treatment of fragile X syndrome and other neurological disorders. Annu Rev Med. 2019. https://doi.org/10.1146/annurev-med-081117-041238.